Announcing General Proximity's $12M, 2x over-subscribed, pre-Series A round.
Medicine is in the dark ages. Our understanding of biology far exceeds our ability to perturb it therapeutically.
How?
~10% of your genome codes for proteins that modify other proteins.
At GP we call this the 'effectome'. The effectome is made up of all post-translational modification (PTM) proteins (readers/writers/erasers), as well as chaperone, adaptor, and trafficking proteins.
A little about our technology.
GP was founded on a simple, first principles premise:
Proximity is inarguably a key regulator of biology and all major disease processes.
Yet only a minuscule fraction of existing drugs work through proximity.
General Proximity (@proxbio) is coming out of stealth.
General Proximity is developing a new class of medicines that we believe has the potential to decrease global disease burden, transform human health, and extend lifespan more than any other current therapeutic modality. 🧵
Fellow academics, when are we going to start fixing our urgent structural problems that strain family bonds and present ongoing barriers to diversifying our educational and scientific leadership? You wonder, what the heck is this guy talking about?
1/n
I'm deeply honored to receive the 2020 Heinrich Wieland Prize and want to thank the many lab members who have helped launch the #targetedproteindegradation field over the past 20 years. #PROTACS#Yale https://t.co/Ki8ni9mKNY